Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca

The second-quarter earnings season was a rather good one for the large drugmakers, with most companies beating estimates for earnings and sales. Particularly a strong top-line performance attracted investor attention to the pharma sector. Driven by the better-than-expected performance in the first half, most companies also raised their guidance for 2023.